Pharmaceutical Manufacturing and Supply – Prochlorperazine Edisylate Injection

The contract mandates the manufacture and supply of Prochlorperazine Edisylate Injection, USP, adhering strictly to USP standards, current Good Manufacturing Practices, and military packaging requirements to ensure quality, safety, and compatibility with defense logistics systems. The product must be produced under rigorous pharmaceutical controls to meet the exacting specifications required for use in military medical environments, with all packaging and labeling compliant with Department of Defense protocols. The subcontract is part of the broader Medical Supply Chain Pharm FSA initiative under the Department of Defense, aimed at securing reliable access to essential pharmacological agents for deployed personnel. The solicitation was posted on May 8, 2026, with a response deadline of May 12, 2026, indicating a tight window for qualified manufacturers to submit proposals. The NAICS code 325412 confirms the scope is specific to pharmaceutical and medicine manufacturing, ensuring only experienced, FDA-registered facilities are eligible to respond. There is no designated set-aside classification, meaning full and open competition is anticipated. The place of performance and point of contact details are unspecified, but the procurement is managed through the DLA BSM system, with all submissions and documentation required via the provided DIBBS portal link. Compliance with military packaging standards implies that the final product must be rugged, stable under field conditions, and ready for immediate deployment without additional repackaging.